Welcome to our dedicated page for CNBX Pharms SEC filings (Ticker: CNBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CNBX Pharms's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CNBX Pharms's regulatory disclosures and financial reporting.
CNBX Pharmaceuticals Inc. reported no revenue for the three and six months ended February 28, 2026 and remained a pre-clinical oncology company focused on its RCC-33 colon cancer candidate. Quarterly operating expenses were $72,963, producing a net loss of $44,098, narrower than the prior-year quarter’s $69,788 loss.
For the six-month period, operating expenses rose to $136,965 and the net loss increased to $157,817 versus $104,140 a year earlier, mainly from higher general and administrative and salary costs. Financial income in the quarter reflected the impact of realizing convertible loans.
CNBX ended the period with only $12,154 in cash and total assets of $14,899, against current liabilities of $2,548,447, leaving a stockholders’ deficit of $(2,533,548). The company converted $120,562 of loans and interest into 571,805,889 new shares, increasing common shares outstanding to 1,225,768,095 as of April 14, 2026. Management and the auditors highlight substantial doubt about CNBX’s ability to continue as a going concern without additional financing.
CNBX Pharmaceuticals Inc. entered into a new short-term financing arrangement. On March 10, 2026, the company executed a non-convertible promissory note with 3i L.P. for $45,000. The note bears simple interest at 5% per year and matures on July 1, 2026.
The company plans to use the proceeds for immediate working capital needs and operating expenditures. This is a relatively small, fixed-rate debt instrument aimed at supporting near-term liquidity rather than long-term expansion.
CNBX Pharmaceuticals Inc.’s large holder 3i and related parties updated their ownership disclosure. They report beneficial ownership of 83,595,541 shares of common stock, all issuable upon conversion of a senior secured convertible note with principal of approximately $655,924.
The note is convertible at an alternate conversion price into up to 83,595,541 shares based on 753,196,666 shares outstanding as of December 31, 2025. A 9.99% beneficial ownership limitation blocks conversions that would push their stake above 9.99%. The investors certify the position is not held to change or influence control of CNBX.
CNBX Pharmaceuticals Inc. reported a larger quarterly loss and severe liquidity pressure for the three months ended November 30, 2025. The company generated no revenue and posted a net loss of $113,719, compared with $34,352 a year earlier, mainly from higher general and administrative expenses and increased interest on loans.
Cash and cash equivalents fell to $7,703, while current liabilities reached $2,584,133, leaving a stockholders’ deficit of $2,572,971. Management and the auditors highlight “substantial doubt” about the company’s ability to continue as a going concern, noting cumulative losses of $25,382,095 and the need for new financing.
To reduce debt, CNBX converted loans and interest totaling $37,041 into 199,234,460 new shares during the quarter, increasing shares outstanding to 753,196,666 at November 30, 2025. Subsequent conversions through early January 2026 added another 117,571,429 shares for $32,920 of debt, further diluting existing holders. The company also relies on forbearance agreements with an institutional investor on a senior secured note while it seeks additional capital.
CNBX Pharmaceuticals Inc. (CNBX) is a Bethesda‑based, clinical‑stage biotech focused on cannabinoid‑based cancer therapies. The company’s lead candidates are Cannabics SR, an oral sustained‑release capsule for cancer anorexia‑cachexia syndrome (CACS), and RCC‑33, a cannabinoid formulation targeting colorectal cancer. Cannabics SR has shown weight gain and appetite benefits in a small peer‑reviewed pilot study, while RCC‑33 has reduced colorectal tumor volume in preclinical models. CNBX plans, contingent on new financing, to run Phase I/II(a) trials for both drugs starting in 2026 and estimates RCC‑33’s early human proof‑of‑concept program at about $6.5 million. The company has no significant revenue, outsources GMP manufacturing, and intends to monetize its pipeline mainly through partnerships and licensing rather than its own sales force. Its auditors have raised substantial doubt about CNBX’s ability to continue as a going concern, and the business depends heavily on raising additional capital and retaining a very small management team.
CNBX Pharmaceuticals (CNBX): Schedule 13G/A Amendment No. 6 filed by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow reports beneficial ownership of 80,865,244 shares, representing 9.99% of CNBX common stock.
The position includes 24,600,000 shares held and 56,265,244 shares issuable upon conversion of a senior secured convertible note, subject to a 9.99% beneficial ownership limitation (the “Blocker”). CNBX had 753,196,666 shares outstanding as of September 30, 2025.
The reporting persons indicate shared voting and dispositive power over 80,865,244 shares and no sole power. They certify the securities are not held for the purpose of changing or influencing control of the issuer.